AstraZeneca PLC has had a disappointing few days with two novel products, with the topline failure of the Phase III SOURCE study of its asthma candidate tezepelumab coming on top of a US approval delay for the anemia in kidney disease therapy roxadustat, announced on 18 December. The UK company had better news, however, with the expanded US approval for Tagrisso (osimertinib) for early-stage EGFR mutant non-small cell lung cancer on the ADUARA study on 21 December.
The initial data from SOURCE show that the potential first-in-class thymic stromal lymphopoietin (TSLP) inhibitor, being jointly developed with
